Diabetes of Unclear Type in an Adolescent Boy With Multiple Islet-cell Autoantibody Positivity Successfully Managed With Glucagon-like Peptide-1 Receptor Agonist Alone: A Case Report.

Authors

Olivia Z B Ginnard
Maria J Redondo
Sarah K Lyons

Publication Date

2-1-2023

Journal

Canadian Journal of Diabetes

DOI

10.1016/j.jcjd.2022.07.006

PMID

36075851

PMCID

PMC10024250

PubMedCentral® Posted Date

2-1-2024

PubMedCentral® Full Text Version

Author MSS

Published Open-Access

yes

Keywords

Humans, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide 1, Autoantibodies, Liraglutide, Insulin, Glucagon-Like Peptide-1 Receptor Agonists, beta-cell reserve, Classification, liraglutide, type 1 diabetes, type 2 diabetes

Abstract

Diabetes classification has traditionally considered type 1 and type 2 diabetes as 2 separate entities with different pathogenic mechanisms. However, clinicians and researchers see increasingly more exceptions to this conventional paradigm, leading to a concept of mixed phenotypes in diabetes classification. Herein we report the case of an adolescent with unclear diabetes type due to the presence of obesity, robust endogenous insulin production, multiple islet autoantibody positivity and severe hyperglycemia at diabetes diagnosis that has been successfully treated with liraglutide therapy alone. Our case report highlights the difficulty of diabetes classification and subsequent need for personalized medicine with regard to diabetes management.